"Systemic thromboxane generation is an independent risk factor for all-cause and cardiovascular mortality irrespective of ASA use, and its measurement may be useful for therapy modification, particularly in those without CVD."

"Systemic TXA₂ generation is an independent risk factor for long-term all-cause and cardiovascular mortality in an unselected cohort of older individuals irrespective of ASA use."

"Urinary 11-dh-TxB2 is a marker of whole-body inflammation and TxA2 biosynthesis contributed by platelet, leukocytes, and endothelial cells [5]."

"Among COVID-19 patients in our study, we found significantly elevated levels of u11-dh-TxB2 in patients with events compared with patients without events, and higher u11-dh-TxB2 levels were associated with prolonged hospitalization, death, and mechanical ventilation requirement. These observations highlight the potential prognostic utility of u11-dh-TxB2 in patients with COVID-19. This is in line with the observations of systemic cytokine storm, endothelial dysfunction, and elevated thrombotic risk in COVID-19."

"The role of inflammation has long been recognized as one of the major factors contributing to initiation and progression of various solid and non-solid malignancies, including hepatocellular carcinoma.  Studies in humans have consistently shown that COX-2 and PGE₂ play an oncogenic role in hepatocellular carcinoma."

"Local aspirin-triggered 15-epilipoxinA₄ production may not only account for aspirin’s anti-inflammatory and antineutrophil actions in vivo, but could be a sensitive new means to directly assess aspirin as well as other acetylation-based anti-inflammatory treatments."

"COX-1 activity and Thromboxane A2 production in platelets contribute to the generation of a permissive early metastatic niche.  Aspirin reduces metastasis through the inhibition of platelet COX-1 and its product Thromboxane A2."

"Systemic low-grade inflammation is a candidate risk factor for prostate cancer in African American men, potentially contributing to lethal prostate cancer development.  Men with high urine thromboxane B₂ were more likely to be diagnosed with prostate cancer metastasis compared to men with low urine thromboxane B₂.  In this study, high urine thromboxane B2 was associated with all-cause mortality and prostate cancer mortality in African American men. Aspirin may reduce lethal prostate cancer in African American Men."

"The stable urinary metabolite of thromboxane A2 (TxA2), urinary 11-dehydro thromboxane B2 (u 11-dh TxB2) has been used as a marker of platelet activation and also response to aspirin therapy. U 11-dh TxB2, in addition to platelet COX-1 activity, also reflects a low-grade inflammatory process of atherosclerosis and activation of inflammatory white cells thus reflecting the whole-body inflammatory state [35]. "

"... an inadequate therapeutic aspirin response (> 1520 pg/mg creatinine) was observed in 91% of COVID-19 patients on 81 mg daily aspirin [18]. The frequency of thromboinflammation (> 4200 pg/mg creatinine) was highest in COVID-19 patients not on aspirin (81%) and lower on 81 mg daily (55%). "

"In COVID-19 patients, u11-dh TxB2 was lower in aspirin-treated patients than patients not on aspirin (3760 ± 2295 versus 13,125 ± 11,474 pg/mg creatinine, p = 0.003). An inadequate therapeutic aspirin response was observed in 91% of COVID-19 patients on 81 mg daily aspirin and 50% of patients on ≥ 162 mg daily aspirin (Fig. 1b). The frequency of thromboinflammation was highest in COVID-19 patients not on aspirin (81%) and lower on 81 mg daily (55%) and lowest on ≥ 162 mg daily aspirin (25%)."

“Previous reports suggest that community-acquired pneumonia (CAP) is associated with an enhanced risk of myocardial infarction (MI) and that enhanced platelet activation may play a role.  Aims of this study were to investigate if urinary excretion of 11-dehydro-thromboxane (Tx) B₂, a reliable marker of platelet activation in vivo, was elevated in CAP and whether glucocorticoid administration reduced platelet activation”.
“Compared to controls, CAP patients showed significantly higher levels of 11-dehydro-TxB₂.  A COX regression analysis showed that 11-dehydro-TxB₂ independently predicted MI.  CAP patients treated with glucocorticoids showed significantly lower levels of 11-dehydro-TxB₂ compared to untreated ones”.

"We investigated markers of platelet reactivity and low-grade inflammation, and their association with early markers of vascular disease in subjects with prediabetes and new onset type 2 diabetes (NDOM)."

"Platelet reactivity was evaluated as 11-dehydrothromboxane B₂ urinary levels (TXB2)"

"TXB2 urinary levels were independently associated with hs-CRP, fibrinogen and HbA1c in multiple regression analysis."